FinTech
Emyria: Reveals “strong recruitment” for EMD-RX5 phase IIItrial
Emyria Reveals “strong recruitment” for EMD-RX5 phase IIItrialEmyria (EMD) announces “strong recruitment” in a phase III clinical trial to facilitate its EMD-RX5 product...
FinTech
Emyria: Raises $3m for clinical trials
Emyria Raises $3m for clinical trialsClinical-stage biotech company Emyria (EMD) has received firm commitments to raise $3 million via a share placement
The...
FinTech
Emyria: Expands drug candidate library with fourth batch of MDMA-inspired analogues
Emyria Expands drug candidate library with fourth batch of MDMA-inspired analoguesEmyria (EMD) progresses its pre-clinical MDMA-inspired drug discovery program with the University of...
FinTech
Emyria: Receives positive screening results for MDMA-inspired analogues
Emyria Receives positive screening results for MDMA-inspired analoguesEmyria (EMD) receives positive screening results from its MDMA novel drug discovery program with the University...
FinTech
Emyria: Expands drug candidate library with third batch of MDMA-inspired analogues
Emyria Expands drug candidate library with third batch of MDMA-inspired analoguesEmyria (EMD) progresses its drug discovery and development of the company’s preclinical MDMA...
FinTech
Emyria: Appoints Sixty Two Capital as corporate advisor for next phase of growth
Emyria Appoints Sixty Two Capital as corporate advisor for next phase of growthEmyria (EMD) appoints Sixty Two Capital as its corporate advisor to...
FinTech
Emyria: Receives positive initial MDMA-analogue screening results
Emyria Receives positive initial MDMA-analogue screening resultsEmyria (EMD) receives positive results from the first batch of MDMA analogues screened for neuroreceptor activity from...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
